Research
A small-molecule compound (not actually a peptide) that blocks an enzyme tied to fat storage. Popular in longevity circles, but only tested in animals so far.
Weight Loss & Metabolism
Research
A lab-made fragment of growth hormone, designed to burn fat without any of growth hormone's other effects. Human trials didn't show it actually works better than placebo.
Clinical Trials
A long-acting amylin-mimicking peptide best known as half of Novo Nordisk's CagriSema combo. Works alongside GLP-1 drugs to suppress appetite even further.
Research
The natural gut hormone that Ozempic and Wegovy are modeled on. Your body already makes it — it just breaks down in minutes, which is why drug versions had to be re-engineered to last longer.
Research Phase
A dual GLP-1/glucagon receptor agonist approved in China for weight management, combining appetite suppression with increased energy expenditure.
Clinical Trials
An experimental triple-hormone injection from Eli Lilly showing the biggest weight-loss results of any drug tested so far. Not yet approved — still in late-stage trials.
FDA Approved
The FDA-approved GLP-1 behind Ozempic and Wegovy. Reduces appetite, blood sugar, and heart disease risk.
Research
An 'exercise in a pill' compound that made mice run further without training, by switching on the same genetic pathway exercise activates. Not a peptide, and untested in humans.
Research Phase
An investigational dual GLP-1/glucagon receptor agonist in Phase 3 trials, designed to combine appetite suppression with increased calorie burning.
FDA Approved
An FDA-approved weekly injection for diabetes and weight loss. Delivers the strongest results of any approved weight-loss medication to date.